BIIB
Biogen · Health Care
2.9%
typical move (median |reaction| of last 8)
2026-10-29 pre · likely
next expected · estimated from pattern
17
scored events
Last eight reactions
2025-10-14 → 2026-07-29
| date | session | reaction | |move| | excess 5s | excess 20s |
|---|---|---|---|---|---|
| 2026-07-29 | pre | +1.4% | 1.4% | -6.7% | +0.7% |
| 2026-07-01 | post | +3.0% | 3.0% | -9.1% | -6.4% |
| 2026-04-29 | pre | +6.1% | 6.1% | -5.0% | -5.0% |
| 2026-04-06 | pre | -2.9% | 2.9% | -1.7% | -0.3% |
| 2026-02-06 | pre | +8.8% | 8.8% | -1.0% | -4.6% |
| 2026-01-13 | post | -5.1% | 5.1% | +2.8% | +17.0% |
| 2025-10-30 | pre | +0.9% | 0.9% | +6.3% | +21.3% |
| 2025-10-14 | post | -1.2% | 1.2% | +2.4% | +9.7% |
Source filings
2026-07-29 · 8-K press release
Cambridge, Mass. – July 29, 2026 Biogen reports strong second quarter 2026 results demonstrating progress toward its goal of sustainable revenue growth • Second quarter 2026 total revenue of $2.7 bill
2026-07-01 · 8-K press release
0000875045 false 0000875045 2026-07-01 2026-07-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exch
2026-04-29 · 8-K press release
Cambridge, Mass. – April 29, 2026 Biogen reports strong first quarter 2026 results First quarter 2026 total revenue of $2.5 billion, increased 2% year-over-year; GAAP diluted EPS of $2.15, increased 3
2026-04-06 · 8-K press release
0000875045 false 0000875045 2026-04-06 2026-04-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exch
2026-02-06 · 8-K press release
Cambridge, Mass. – February 6, 2026 Biogen reports strong fourth quarter and full year 2025 results and provides full year 2026 financial guidance Fourth quarter 2025 total revenue $2.3 billion; GAAP
2026-01-13 · 8-K press release
0000875045 false 0000875045 2026-01-13 2026-01-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exch
2025-10-30 · 8-K press release
Cambridge, Mass. – October 30, 2025 Biogen reports strong third quarter 2025 results and updates full year 2025 guidance Third quarter 2025 total revenue of $2.5 billion, increased 3% year-over-year;
2025-10-14 · 8-K press release
0000875045 false 0000875045 2025-10-14 2025-10-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exch